FLUOGUIDE A/S DK -1 (96X) - Total Liabilities
Based on the latest financial reports, FLUOGUIDE A/S DK -1 (96X) has total liabilities worth €33.76 Million EUR (≈ $39.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 96X net asset momentum to track the company's year-over-year net asset growth rate.
FLUOGUIDE A/S DK -1 - Total Liabilities Trend (2021–2025)
This chart illustrates how FLUOGUIDE A/S DK -1's total liabilities have evolved over time, based on quarterly financial data.
FLUOGUIDE A/S DK -1 Competitors by Total Liabilities
The table below lists competitors of FLUOGUIDE A/S DK -1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TronicS Microsystems SA
PA:ALTRO
|
France | €17.73 Million |
|
Do Day Dream Public Company Limited
BK:DDD
|
Thailand | ฿309.00 Million |
|
Adolfo Dominguez SA
MC:ADZ
|
Spain | €88.19 Million |
|
Selangor Dredging Bhd
KLSE:2224
|
Malaysia | RM616.84 Million |
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
Germany | €1.97 Billion |
|
Sherritt International Corporation
TO:S
|
Canada | CA$715.50 Million |
|
Raphas Co. Ltd
KQ:214260
|
Korea | ₩42.41 Billion |
|
Ionic Rare EARTHS Ltd
AU:IXR
|
Australia | AU$2.97 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down FLUOGUIDE A/S DK -1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FLUOGUIDE A/S DK -1 market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how FLUOGUIDE A/S DK -1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for FLUOGUIDE A/S DK -1 (2021–2025)
The table below shows the annual total liabilities of FLUOGUIDE A/S DK -1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €33.76 Million ≈ $39.47 Million |
+535.50% |
| 2024-12-31 | €5.31 Million ≈ $6.21 Million |
-68.54% |
| 2023-12-31 | €16.89 Million ≈ $19.75 Million |
+362.46% |
| 2022-12-31 | €3.65 Million ≈ $4.27 Million |
-75.00% |
| 2021-12-31 | €14.61 Million ≈ $17.08 Million |
-- |
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more